Analysts Set Halozyme Therapeutics, Inc. (HALO) Target Price at $21.00
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $21.00.
Several equities analysts recently commented on the company. BidaskClub raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. Piper Jaffray Companies reissued a “neutral” rating on shares of Halozyme Therapeutics in a research report on Friday, October 19th. Cantor Fitzgerald reissued a “buy” rating and set a $27.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, December 5th. Finally, ValuEngine raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.
Institutional investors and hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $123,000. Verition Fund Management LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $182,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $205,000. Trexquant Investment LP acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $207,000. Finally, Raymond James & Associates acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $222,000. 83.91% of the stock is currently owned by institutional investors.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. The firm had revenue of $25.60 million for the quarter, compared to analyst estimates of $30.42 million. Halozyme Therapeutics had a return on equity of 18.87% and a net margin of 16.24%. Halozyme Therapeutics’s revenue for the quarter was down 59.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.02 EPS. Sell-side analysts expect that Halozyme Therapeutics will post -0.56 EPS for the current year.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Further Reading: Average Daily Trade Volume – ADTV
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.